Back to search
FDAFDA · Food and drugs·Recall number Z-2896-2026

5-PLASMA Bivalirudin Control, Model Number 5D-44905

Published August 12, 2026 · Recall initiated: July 1, 2026

Summary

FDA records medical device Class II recall Z-2896-2026, published August 12, 2026 and initiated July 1, 2026. Recalling firm: Aniara Diagnostica LLC; Status: Ongoing; Reported quantity: 9 units; Lot: UDI-DI: 05070002420385, Lot Number: KE132602. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Stability issues with the reconstituted lyophilized human plasma and bivalirudin matrix have been identified. These stability issues lead to a degradation of measurable bivalirudin in the controls, calibrators, and linearity values.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Aniara Diagnostica LLC
Distributor
US Nationwide distribution in the states of IL, NC, TN.
Lot
UDI-DI: 05070002420385, Lot Number: KE132602
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was 5-PLASMA Bivalirudin Control, Model Number 5D-44905 recalled?

Yes. FDA published recall Z-2896-2026 on August 12, 2026. Reported hazard: Stability issues with the reconstituted lyophilized human plasma and bivalirudin matrix have been identified. These stability issues lead to a degradation of measurable bivalirudin in the controls, calibrators, and linearity values.

What should I do if I have this product?

Voluntary: Firm initiated · Letter